Skip to main content

Highlights

  1. 1
    JAMA · 2025
    PMID: 39616603PMCID: PMC11610526DOIFirst author50 citations
  2. 2
    JAMA internal medicine · 2022
    PMID: 35285851PMCID: PMC8922207DOISenior author70 citations
  3. 3
    Harm reduction journal · 2021
    PMID: 34819070PMCID: PMC8611635DOISenior author56 citations

Publications

68 publications

Active

7 grants
  • KP
    Columbia University-Weill Cornell Medicine CFAR (CU-WCM CFAR)
    National Institute of Allergy and Infectious Diseases · 2026–2031 · via Columbia University
    P30AI191337-01A1
  • Co-I
    Research Training in Infectious Diseases
    National Institute of Allergy and Infectious Diseases · 2020–2030· 2 renewals
    T32AI007613-26A1
  • Co-I
    Hormone Therapy for Peri- and Postmenopausal Women with HIV (HoT): ACTG A5424
    National Institute on Aging · 2025–2028 · via University of North Carolina at Chapel Hill
    R01AG081155-03
  • MPI
    ACTG Leadership and Operations Center (LOC) - CRS 7804
    National Institute of Allergy and Infectious Diseases · 2012–2027 · via University of North Carolina at Chapel Hill· 9 renewals
    UM1AI068636-20
  • KP
    Weill Cornell Medicine - Rutgers New Jersey Medical School Clinical Trials Unit
    National Institute of Allergy and Infectious Diseases · 2013–2027· 2 renewals
    UM1AI069419-15
  • Sub-PI
    The Role of Sleep in Cardiovascular Health Among Men Living With HIV
    National Heart, Lung, and Blood Institute · 2024–2027 · via Rutgers, The State University of New Jersey – New Brunswick
    R01HL156788-05
  • Co-I
    HIV Prevention Trials Network (HPTN106 FHI360 - WCM)
    National Institute of Allergy and Infectious Diseases · 2020–2026 · via FHI 360· 2 renewals
    UM1AI068619-19
Completed grants (12)
  • MPI
    ACTG LOC (A5415 FDG PET/CT Scans)
    National Heart, Lung, and Blood Institute · 2023–2024 · via University of California, Los Angeles
    R01HL149516-01A1
  • MPI
    1/2 REPRIEVE Extension for Trial Completion
    National Heart, Lung, and Blood Institute · 2023–2024 · via The General Hospital Corporation (dba Massachusetts General Hospital)
    UG3HL164285-01
  • Sub-PI
    CoVPN 3001: Phase 3, SARS-CoV-2 Vaccine (Moderna TX, Inc.)
    National Institute of Allergy and Infectious Diseases · 2020–2023 · via FHI 360
    FHI 210569-01
  • Sub-PI
    CoVPN 3004: Phase 3, SARS-CoV-2 Vaccine (Novavax)
    National Institute of Allergy and Infectious Diseases · 2020–2023 · via FHI 360
    5 UM1 AI068619615
  • MPI
    Pitavastatin to Reduce Physical Function Impairment and FRailty in HIV (PREPARE) - A5332 substudy A5361s: 1560 B WB699
    National Institute on Aging · 2018–2023 · via University of California, Los Angeles
    R01AG054366-05
  • MPI
    A5332: Prevention of Vascular Events in HIV - REPRIEVE & Substudy A5333s: Pitavastatin on CAD & Inflammatory Biomarkers
    National Heart, Lung, and Blood Institute · 2014–2023 · via The Brigham & Women's Hospital INC
    U01HL123336-01
  • MPI
    Effect of Pitavastatin on Kidney Function in HIV-infected Persons - CRS 7804 1560 B XA868
    National Institute of Diabetes and Digestive and Kidney Diseases · 2018–2022 · via University of California, Los Angeles
    R01DK108438-05
  • Sub-PI
    Accessible Care Intervention for Engaging People who Inject Illicit Drugs (PWID) in Hepatitis C Care
    National Institute on Drug Abuse · 2016–2021 · via Research Foundation of CUNY· 2 renewals
    R01DA041298-04
  • KP
    AIDS Education and Training Centers Program (AETC)
    Health Resources and Services Administration · 2015–2019 · via Columbia University
    5 U1O HA29291-02
  • PI
    Rates of Mixed Hepatitis C Infection in Active Injection Drug Users and the Impact of Low Level Mixed Infection on Treatment Outcomes
    Bristol-Myers Squibb · 2015–2018
    BMS AI444-385
  • PI
    Thrombocytopenia & HIV/HCV: Risk Factors & Treatment
    NIAID · 2005–2010 · via NIH RePORTER
    K23AI065319-05
  • MPI
    SAFETY/EFFICACY OF IV ANTI-D FOR TREATMENT OF THROMBOCYTOPENIA IN HCV
    NCRR · 2005–2007 · via NIH RePORTER
    M01RR000047-47

Clinical research

18 studies

Active

3 studies
  • PI
    A5432: Optimizing Implementation of Long-Acting ART and Implementation Research (LATIR) in the ACTG through Qualitative Research with A5359 Trial Participants and Study Staff
    National Institute of Allergy & Infectious Diseases · OPEN TO ACCRUAL (as of 2026)
  • PI
    A5321:Decay of HIV-1 Reservoirs in Participants on Long-Term Antiretroviral Therapy: The ACTG HIV Reservoirs Cohort (AHRC) Study
    National Institute of Allergy & Infectious Diseases · OPEN TO ACCRUAL (as of 2025)
  • PI
    The Role of Sleep in Cardiovascular Health Among Men Living with HIV
    Rutgers, The State University of New Jersey · OPEN TO ACCRUAL (as of 2024)
Completed & closed trials (15)
  • PI
    Safety, Tolerability, and Impact of Oral TLR8 Agonist Selgantolimod on HBsAg in Participants With Both Chronic Hepatitis B and HIV
    PHASE2 · National Institute of Allergy & Infectious Diseases · IRB STUDY CLOSURE (as of 2026)
    Hepatitis B; HIV Infections
    NCT05551273
  • PI
    A Phase 3b, Open Label, Randomized, standard-of Care Control Arm, Multicenter, Superiority Study Evaluating the Efficacy, Safety, and Tolerability of Injectable CAB LA + RPV LA in Viremic Participants Living With HIV-1 (CROWN)
    PHASE3 · VIIV Healthcare · CLOSED TO ACCRUAL (as of 2026)
    HIV Infections
    NCT06694805
  • PI
    A Proposal to Cure HCV And Guide Engagement among People Living with HIV (CHANGE)
    Columbia University Medical Center · IRB STUDY CLOSURE (as of 2025)
  • PI
    A Phase 2, Open-label, Multicenter, Randomized Study to Evaluate the Pharmacokinetics, Safety, and Acceptability of Twice Yearly Long-acting Subcutaneous Lenacapavir for Pre-Exposure Prophylaxis in Cisgender Women in the United States
    PHASE2 · Gilead Sciences, Inc. · CLOSED TO ACCRUAL (as of 2025)
    Pre-Exposure Prophylaxis of HIV Infection
    NCT06101329
  • PI
    B-Enhancement of HBV Vaccination in Persons Living With HIV (BEe-HIVe): Evaluation of HEPLISAV-B
    PHASE3 · National Institute of Allergy & Infectious Diseases · IRB STUDY CLOSURE (as of 2025)
    HIV Infection; Hepatitis B
    NCT04193189
  • PI
    Randomized, Controlled Trial to Evaluate the Anti-inflammatory Efficacy of Letermovir (Prevymis) in Adults With Human Immunodeficiency Virus (HIV)-1 and Asymptomatic Cytomegalovirus (CMV) Who Are on Suppressive ART and Its Effect on Chronic Inflammation, HIV Persistence, and Other Clinical Outcomes
    PHASE2 · National Institute of Allergy & Infectious Diseases · IRB STUDY CLOSURE (as of 2024)
    HIV Infections; Cytomegalovirus; CMV
    NCT04840199
  • PI
    Glecaprevir/Pibrentasvir Fixed-dose Combination Treatment for Acute Hepatitis C Virus Infection (PURGE-C)
    PHASE2 · National Institute of Allergy & Infectious Diseases · IRB STUDY CLOSURE (as of 2024)
    Hepatitis C Infection; HIV Infection
    NCT04042740
  • PI
    A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1™ Adjuvant in Adult Participants ≥ 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years)
    PHASE3 · Novavax, Inc · IRB STUDY CLOSURE (as of 2023)
    SARS-CoV Infection; Covid19
    NCT04611802
  • PI
    A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older
    PHASE3 · ModernaTX · IRB STUDY CLOSURE (as of 2023)
    SARS-CoV-2
    NCT04470427
  • PI
    Individual Patient Emergency Compassionate Use with Casirivimab and Imdevimab
    Weill Medical College of Cornell University · IRB STUDY CLOSURE (as of 2023)
  • PI
    COVID-19 Prevention Network (CoVPN) Screening
    Weill Medical College of Cornell University · IRB STUDY CLOSURE (as of 2022)
  • PI
    Glecaprevir/Pibrentasvir Fixed-dose Combination Treatment for Acute Hepatitis C Virus Infection (PURGE-C)
    PHASE2 · National Institute of Allergy & Infectious Diseases · IRB STUDY CLOSURE (as of 2021)
    Hepatitis C Infection; HIV Infection
    NCT04042740
  • PI
    Remdesivir (RDV; GS-5734) for the Treatment of Selected Coronavirus (CoV) Infection
    Gilead Sciences, Inc. · IRB STUDY CLOSURE (as of 2021)
  • PI
    A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe COVID-19
    PHASE3 · Gilead Sciences, Inc. · IRB STUDY CLOSURE (as of 2020)
    COVID-19
    NCT04292899
  • PI
    A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate COVID-19 Compared to Standard of Care Treatment
    PHASE3 · Gilead Sciences, Inc. · IRB STUDY CLOSURE (as of 2020)
    COVID-19
    NCT04292730

News mentions

  • Awards & Honors: May 2026
    May 29, 2026

    Awards, honors and achievements for the month of May.

  • Awards & Honors: December 2025
    December 31, 2025

    Awards, honors and achievements for the month of December.

  • Updated Hep B Vaccine More Effective for People with HIV
    December 11, 2024

    A newer vaccine against hepatitis B virus was clearly superior to an older vaccine type in inducing a protective antibody response among people living with HIV who didn’t respond to prior vaccination, according to the results of an international study led by a Weill Cornell Medicine investigator.

  • Accessible Care Key to Treating Hepatitis C in People Who Inject Drugs
    April 7, 2022

    Among participants who had hepatitis C and who injected drugs, those treated at a non-stigmatizing “accessible care” treatment center co-located with a syringe service program (SSP) were nearly three times more likely to be cured of the infectious disease compared with those referred out to local clinicians through patient navigation, according to a randomized clinical trial led by investigators at Weill Cornell Medicine, NewYork-Presbyterian, NYU Grossman School of Medicine, and the CUNY Graduate School of Public Health and Health Policy.

  • Mission Possible: Weill Cornell Medicine Launches an Unprecedented Research Effort in the Battle Against COVID-19
    March 2, 2021

    Soon after the first case of COVID-19 was reported in New York City last March, a group of about 10 physician-scientists at Weill Cornell Medicine met to discuss a pressing issue: there were no known treatments for severe cases of the disease.

Show 5 more mentions
  • COVID-19 Vaccines and Immunity: How Long Does it Take for the Vaccines to Provide Protection?
    February 11, 2021

    With the COVID-19 vaccines rolling out across the country and more people getting vaccinated, many are wondering how long it takes for the vaccines to provide protection.

  • Five Facts About the COVID-19 Vaccine
    January 21, 2021

    The COVID-19 vaccine rollout is underway, bringing a sense of hope — as well as many questions about safety and who should get the vaccine. To help answer these questions, NewYork-Presbyterian experts address common concerns about the new Moderna and Pfizer-BioNTech COVID-19 vaccines and explain why they are safe.

  • COVID-19 Vaccine: Your Top Questions Answered
    December 16, 2020

    As the coronavirus vaccine rolls out across the country, an infectious disease expert answers questions about its safety and when it’s likely to be available to the general public.

  • Dr. Kristen Marks on Science, Safety and the Timeline of a COVID-19 Vaccine
    August 20, 2020

    Dr. Kristen Marks, an associate professor of medicine in the Division of Infectious Diseases at Weill Cornell Medicine and associate attending physician at the medical center, leads the team conducting Moderna Therapeutics’s phase 3 COVID-19 vaccine trial at NewYork-Presbyterian/Weill Cornell Medical Center—one of dozens of medical centers around the U.S. where this still-experimental vaccine will be tested.

  • Weill Cornell Medicine and NewYork-Presbyterian Conduct Clinical Trials for COVID-19 Drugs
    May 8, 2020

    As doctors face the novel coronavirus that causes COVID-19 with a very limited arsenal of treatments, physicians at Weill Cornell Medicine and NewYork-Presbyterian have rapidly mobilized to test candidate drugs in clinical trials.

External relationships

Other

Novo Nordisk Pharmaceuticals, Inc.